"Biocodex USA is thrilled to be attending AES this year. We are dedicated to bringing new data to our health care providers ...

At the center of a new licensing deal is an experimental medicine, PTC518, which is currently being tested in a roughly ...

Members of the Philippine Health Insurance Corp. (PhilHealth) will soon enjoy enhanced benefit packages, which include coverage for rare diseases, expected to be available in early 2025. ICYMI, the ...

As the NHS explores extended genetic screening for newborns, Paul Dinsdale investigates the perils and pitfalls of genomic ...

Philippine Health Insurance Corporation (PhilHealth) announced on Monday new benefit packages covering various illnesses as ...

Newborn screening, conducted within the first 24-48 hours post-birth, identifies hidden genetic, metabolic, and endocrine ...

Despite the “unfortunate” failure, William Blair analysts do not believe that the utreloxastat readout will heavily affect ...

But utreloxastat had little effect on ALS in the phase 2 trial. PTC powered the study to show whether twice-daily oral dosing ...

Eton Pharmaceuticals has acquired the US rights to Amglidia, a treatment developed for neonatal diabetes mellitus, from France-based biotechnology company AMMTeK. Amglidia, also known as glibenclamide ...

Biomarin has a near $3bn per annum drug franchise, and is profitable. Elliott Investment Management may be attempting to ...

Senator Christopher “Bong” Go, the chairperson of the Senate Committee on Health and Demography, has expressed optimism over ...

NGGT has initiated Phase I/II clinical trials in the U.S. and China to evaluate the safety and efficacy of NGGT002 for the treatment of Phenylketonuria WALNUT CREEK, Calif., Nov. 11, 2024 /PRNewswire/ ...